CONTINUING EDUCATION:
RN, NP:  1 CE Credit

Recorded Date:  April 12, 2014 (as part of the 2014 PCNA annual symposium in Atlanta)
Original Posting Date: March 2, 2016
Content Review Date: March 2016

COURSE OVERVIEW:

First author of the 2013 prevention guidelines Neil Stone provides clinicians practical examples of the application of the guidelines.

AUDIENCE:
Nurses, advanced practice nurses, and other healthcare providers interested in the prevention and management of cardiovascular disease.

FACULTY DISCLOSURES:
The faculty members have declared no commercial relationships related to the content of this presentation.

COST:
This online educational activity is offered free of charge.

PARTICIPATION IN THE ACTIVITY AND RECEIPT OF CERTIFICATE OF CREDIT:
View the course materials; complete the post-test (you can take the post-test more than once if needed to achieve a passing score of 75%) and online evaluation form at the end of the activity, and print your CE certificate.

ACCREDITOR:
This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). PCNA is approved as a provider of nurse practitioner continuing education (CE) programs by the American Association of Nurse Practitioners (AANP), provider number 030602. This program is accredited for 1 contact hours of continuing education. This program was planned in accordance with AANP CE Policies and Commercial Support Standards.

Please note that if you received credit for attending the 2014 PCNA Annual Symposium in Atlanta, you will be unable to claim credit for the on-demand sessions that were recorded there.  

Identify the role of lifestyle modification (i.e., adhering to a heart healthy diet, regular exercise habits, avoidance of tobacco products, and maintenance of a healthy weight) as a critical component of health promotion and ASCVD risk reduction, both prior to, and in concert with, the use of cholesterol-lowering drug therapies.
List the four groups of patients identified in the updated guidelines for whom an extensive body of RCT evidence demonstrated a reduction in atherosclerotic cardiovascular disease (ASCVD) events with a good margin of safety from statin therapy.
Describe how the focus on treating risk, not LDL, changes the clinical encounter for a high risk primary prevention patient.